Google
GRFS 株価分析 — GRIFOLS SA ADR (Healthcare >> Drug Manufacturers - General)
GRFS に関するよくある質問
GRFSのPER（株価収益率）は？
GRIFOLS SA ADR（GRFS）は現在PER 12.33倍で取引されています。
GRFSのROE（自己資本利益率）は？
GRIFOLS SA ADRのROEは8.16%です。
GRFSの配当利回りは？
GRIFOLS SA ADRの配当利回りは3.43%です。
GRFSの品質スコア（Quality Score）は？
当社のAIはGRFSの総合財務品質を100点中62点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
GRFSは今が買い時ですか？
当社AIのタイミングスコアは100点中63点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
GRFSはどのセクターに属しますか？
GRIFOLS SA ADRはHealthcare >> Drug Manufacturers - Generalセクターに分類されます（NASDAQ市場）
GRFS AI Analysis Summary
Our AI summary for GRFS: GRIFOLS SA ADR (NASDAQ), Healthcare >> Drug Manufacturers - General sector. The stock currently trades at a P/E of 12.33, ROE of 8.16%, a dividend yield of 3.43%. Its financial Quality Score stands at 62/100 — mid-range fundamentals relative to the market. The AI Timing Score is 63/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 7.87
Price
-0.33
(-4.02%)
Day Change
|
|
|---|
GRFS, ファンダメンタルスコアはok ( ファンダメンタル = 62) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
ROEが低い
平均ROEが低い
ROAがROEに比べて低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
57% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 74 |
| Magic Formula Rank by ROA |
1665
|
| Magic Formula Rank by ROE |
1665
|
| Magic Formula Rank by ROIC |
1289
|
| Price | 7.87 |
| PBV / Sector |
0.70 / 2.68
GREAT
|
| Earning Per Share | 0.64 |
| PE / Sector |
12.33 / 27.65
GOOD
|
| PEG or PE/Growth / Sector |
0.11 / 0.28
GREAT
|
| Average 1M Daily Value |
5.27 M
GREAT
|
| Average 1W Daily Value |
8.31 M
|
| Timing Factors |
|
71% |
| Financial Health |
|
39% |
| ポイントになる統計 |
|
62% |
| 配当 |
|
62% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:55 |
| Symbol | GRFS |
| Name | GRIFOLS SA ADR |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NASDAQ |
| Listed Shares | 258.22 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 5,580.76 / 256,404.20 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Parque Empresarial Can Sant Joan, Barcelona, Spain, 08174
Phone: 34 935 71 22 00
Website: https://www.grifols.com
Employees: 25,000
Description: Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
